Category: RRT ResearchPresenter: Dr FARIZ SAFHAN MOHAMAD NOR Keywords: vancomycin, continuous renal replacement therapy, pharmacokinetic Introduction: Achieving optimal vancomycin dosing, particularly in septic critically ill patients receiving continuous renal replacement therapy (CRRT) is crucial. Established guidelines recommend the use of trough concentrations to manage vancomycin dosing in adult patients with gram-positive infections. Importantly, obtaining the area under the plasma concentration-time curve (AUC), based on the pharmacokinetic / pharmacodynamics (PK/PD) concept, is extremely required.Objective: This study aimed to describe the pharmacokinetics (PK) of vancomycin in Malaysian critically ill patients receiving CRRT, and the achievement of its therapeutic target, the ratio of the AUC to the minimum inhibitory concentration (MIC) of causative pathogen (AUC/ MIC >400), using a standard dosing regimen (750 mg 12 hourly). Methodology: This was a prospective PK study of vancomycin using standard dosing regimen, in critically ill patients receiving continuous venovenous haemofiltration (CVVH). Blood samples were collected at ten sampling times during a dosing interval. PK analyses were evaluated using non-compartmental method. Vancomycin trough concentrations (15-20 mg/L), and the achievement of the ratio of AUC/ MIC>400, based on selected susceptibility breakpoint (MIC¼1 mg/L), were evaluated. Results: Fifty blood samples from five PK profiles of five patients were analysed. The median (interquartile range) of vancomycin total clearance (CL total ) and volume of distribution (V d ) were 62.8 (45.1-62.7) mL/ min and 62.0 (48.7-94.2) L respectively, during CVVH. Maximum concentration, C max [30.8 (30.5-33.2) mg/L] was observed at 1.8AE0.3 h. The standard dosing regimen (750 mg 12 hourly) resulted in AUC 0-24 and C min of 400.1 (399.0-504.1) mg.h/L and 12.1 (10.7-16.1) mg/L, respectively. Of these, only two patients, who were anuric, obtained trough concentration between 15-20 mg/L and subsequently achieved the targeted AUC/MIC>400 (MIC¼1 mg/L).
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
customersupport@researchsolutions.com
10624 S. Eastern Ave., Ste. A-614
Henderson, NV 89052, USA
Copyright © 2024 scite LLC. All rights reserved.
Made with 💙 for researchers
Part of the Research Solutions Family.